iShares Core S&P Small Cap

Strategy Report

.SPX

SOXS

.IXIC

SQQQ

GLDM

SDOW

SGOL

SOXL

TQQQ

UPRO

<p>A hand-controlled life necessity price, plus a man-made interest price, will ochestrate US' economy boom in 2036.</p>

VanEck Semiconductor ETF

iShares Core S&P Mid Cap

S&P 500

Direxion Semicon Bear 3X

iShares Gold Trust

NASDAQ Composite Index

Proshares UltraPro Short QQQ ETF

SPDR Gold Minishares

SPDR Gold Shares

ISHRS Russ 1000

iShares Core S&P 500

Invesco QQQ Trust

Pro UltrPro Shrt Dow30

Abrdn Gold ETF Trust

Direxion Semicon Bull 3X

Proshares UltraPro QQQ

Pro Ultr Bloomberg Crude Oil

Pro UltrPro S&Pro 500

United States Oil Fund LP

C3.AI

3% US 2026 GDP—New Policy Floor of AI Era?

ABTC

GBTC

SBET

<p>Continued tight liquidity has started to affect beneficiaries under ample liquidity, such as Bitcoin, as well as tech growth stocks with weak fundamentals and excessive valuations. But what cause the liquidity shortage abruption? what may ease it? and how to position portfolios under this circumstance?</p>

American Bitcoin

Grayscale Bitcoin Trust BTC - ETF

SharpLink Gaming

Angel Oak Mortgage-Backed Securities ETF

ON Semiconductor

U.S. gov. shutdown to trigger a 'dollar shortage'?

B. Riley Securities analyst reiterates SPX buy rating

Arrowhead Pharmaceuticals Inc. Director Michael S. Perry Sells Common Stock

Analyst Patrick Trucchio Reiterates Buy Rating on Arrowhead Pharmaceuticals with a Target Price of $85

Lumen Technologies Inc. Issues $1.25 Billion Senior Notes

Morgan Stanley Maintains Hold Rating on Arrowhead Pharmaceuticals with Price Target of $48

InterDigital Inc. CTO Reports Sale of Company Common Stock

Morgan Stanley Downgrades BorgWarner Rating, Stock Falls

SPX Acquires Crawford United Corporation

Arrowhead Pharmaceuticals Launches ARO-MAPT Clinical Trial for Alzheimer's Disease

Lumen's Subsidiary Plans to Issue Senior Notes to Repurchase Existing Bonds

Arrowhead Pharmaceuticals Announces First Commercial Launch of RNA Interference Therapy REDEMPLO® in 2025

First Trust Advisors LP Reduced Holdings in Lumen Technologies

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

JPMorgan Cuts Stake in BorgWarner

LUMN Shares Continue Seventh Day Rally, Analysts Bullish on Future Performance

Hecla Mining Company Emphasizes Its Leadership in Silver Mining

Lumen Restarts Signature Teacher and Technology Funding Program With $1 Million Grant

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Director Reports Sale of Company Common Stock

Hecla Mining Company Receives Approval for Exploration Project from US Forest Service